tbuckley/cabot-search huggingface dataset:
AB0126 MULTIPARAMETER LINEBLOT IMMUNOASSAY FOR AUTOIMMUNE INFLAMMATORY MYOPATHIES: ADDITION OF cN-1A FOR THE DETECTION OF AUTOANTIBODIES ASSOCIATED WITH INCLUSION BODY MYOSITIS
Authors: J. Janz, A. Ott, M. Richter, T. Scheper, W. Schlumberger, W. Meyer
Journal: Annals of the Rheumatic Diseases (2022)

Background Autoantibodies against cN-1A (Mup44) are primarily used as a biomarker for inclusion body myositis (IBM), they also occur with lower prevalence in systemic lupus erythematosus (SLE) and Sjögren’s Syndrome (SjS). cN-1A has been included as a parameter on the multiparameter lineblot Autoimmune Inflammatory Myopathies 16 Ag et cN-1A (EUROIMMUN), allowing the detection of 17 myositis-specific and myositis-associated autoantibodies. Objectives The prevalences of anti-cN-1A autoantibodies were determined in different patient collectives and healthy blood donors. Methods A lineblot immunoassay containing a highly purified, recombinant cN-1A expressed in E.coli was incubated according to the instructions. Sera of 197 patients with IBM, 48 with collagenosis (systemic sclerosis, undifferentiated collagenosis and mixed tissue collagenosis), 52 with polymyositis/dermatomyositis and 75 with SLE/SjS were screened for cN-1A autoantibodies. Additionally, 151 apparently healthy blood donors as well as a disease control collective comprising sera of 20 patients with thyroiditis, 26 with neuromuscular disorders, 24 with primary biliary cholangitis (PBC), 19 with Wegener’s Disease, 17 with Coeliac disease, and 2 with autoimmune liver disease (ALD) were analyzed. Signal intensities were automatically evaluated using the EUROLineScan software (EUROIMMUN). Results Prevalences of cN-1A autoantibodies were 34.5% in IBM, 10.4% in collagenosis, 7.7% in polymyositis/dermatomyositis, 13.3% in SLE/SjS, 2% in the blood donor cohort and 4.6% in the disease control collective. Conclusion The addition of cN-1A to a multiparametric lineblot immunoassay now reduces the risk of underdiagnosing IBM in patients with autoimmune inflammatory myopathies and increases the overall diagnostic sensitivity. Disclosure of Interests Julia Janz Employee of: EUROIMMUN Medizinische Labordiagnostika AG, Anthonina Ott Employee of: EUROIMMUN Medizinische Labordiagnostika AG, Marius Richter Employee of: EUROIMMUN Medizinische Labordiagnostika AG, Thomas Scheper, Employee of: EUROIMMUN Medizinische Labordiagnostika AG, Wolfgang Schlumberger Employee of: EUROIMMUN Medizinische Labordiagnostika AG, Wolfgang Meyer Employee of: EUROIMMUN Medizinische Labordiagnostika AG
AB0244 MEDICATION ADHERENCE AND BELIEFS ABOUT MEDICATION IN PATIENTS WITH RHEUMATOID ARTHRITIS.
Authors: C. Jugel, C. Baerwald, O. Seifert
Journal: Annals of the Rheumatic Diseases (2022)

Background Consistent immunosuppressive treatment of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drugs (DMARDs) is crucial for reduced progression and improved long-term outcome of the disease. Therefore, drug adherence is a prerequisite, which is often insufficient according to literature. Objectives Our aim was to investigate the relationship between adherence and beliefs about medication in patients with RA. Methods The study included 137 RA patients (102 female, 35 male; age range 28-86 years, Ø 64.8 ± 12.6 yrs; SDAI Ø 9.9 ± 6.8; 61 % DMARD monotherapy, 31 % DMARD combination therapy, 9 % currently treated without DMARD). Medication adherence was measured with the Compliance-Questionnaire-Rheumatology (CQR). This is a self-report questionnaire with 19 items (4 response options each). The sum score is mapped to a scale from 0 to 100 % (CQR%), where 100 % corresponds to optimal adherence. A CQR% ≥ 80 % was defined as satisfactory adherence. In addition, the specific part of the Beliefs about Medicines Questionnaire (BMQ) was used to assess patients’ opinions about the necessity of their medication therapy and their concerns. Besides correlation analyses (Spearman-Rho) multiple linear regression was applied to determine factors influencing adherence (coefficient of determination: adjusted R 2 ). Results Adherence was satisfactory in 93 RA patients (67.9 %) and insufficient in almost one-third (n = 44, 32.1 %). Analyses showed that adherence was significantly related to belief in necessity (r = 0.46; p &lt; 0.001) and concerns about drug therapy (r = -0.27; p = 0.001). Furthermore, it became apparent that adherence is closely linked to the age of the patient (r = 0.30; p &lt; 0.001). Younger RA patients (&lt; 60 yrs) had significantly lower CQR%-scores than older RA patients (≥ 60 yrs; p &lt; 0.01). Belief in the necessity of therapy, medication concerns and patient age accounted for almost half of the patient-specific variability in adherence (each p &lt; 0.001; R 2 = 42.9 %), suggesting a strong dependence of adherence on these three factors. Conclusion Adherence is insufficient in about one-third of RA patients. Additionally, adherence appears to be strongly dependent on the patient’s belief in the necessity of therapy, medication concerns and age. Physicians should strive for all RA patients to have sufficient knowledge about their medication, strengthen the belief in the necessity of the therapy and be mindful of adherence when talking to patients. Disclosure of Interests None declared
Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya: an open-label, randomised, non-inferiority, implementation trial
Authors: Kenneth Ngure, Katrina F Ortblad, Peter Mogere, Ashley R Bardon, Katherine K Thomas, Dorothy Mangale, Catherine Kiptinness, Stephen Gakuo, Sarah Mbaire, Jacinta Nyokabi, Nelly R Mugo, Jared M Baeten
Journal: The Lancet HIV (2022)
Basal cell carcinoma shows weak correlation with pre-existing chronic lymphocytic leukemia: A case-control study
Authors: Brian Cheng, Surya Veerabagu, Christopher J. Miller, Joseph F. Sobanko, Thuzar M. Shin, Cerrene N. Giordano, Jeremy R. Etzkorn, H. William Higgins
Journal: Journal of the American Academy of Dermatology (2022)
AB1043 IDENTIFICATION OF UNUSUAL TOPHI ANTERIOR TO THE THYROID CARTILAGE USING DIFFERENT IMAGING METHODS
Authors: Y. Jiang, X. Wu, Z. Liao, J. Qi, J. Gu
Journal: Annals of the Rheumatic Diseases (2022)

Background Inadequately treated gout patients could develop tophi. However, tophi could appear as atypical mass, leading to difficulty in differential diagnosis. Objectives The objectives of the study were to describe an unusual case with tophi anterior to the Thyroid Cartilage using different imaging methods. Methods Clinical information of the case was presented. Ultrasound, dual energy Computed Tomography (DECT) and CT scan were compared to describe the tophi. Results A 66-year-old man with a 30-year history of gout was admitted. He had received urate-lowering drugs intermittently over the past few years. Physical examination revealed multiple tophi on the hands, feet, and other auricular surfaces. Moreover, there was a subcutaneous mass above the thyroid cartilage (Figure 1A). Ultrasound revealed hyperechoic nodule anterior to the thyroid cartilage, 11*7cm in size, with uneven internal echo, no blood flow signal inside, and a close relationship between the barrier of the nodule and the thyroid cartilage (Figure 1B). DECT of the neck confirmed that the mass anterior to the thyroid cartilage were tophi (Figure 1C-D). A plain radiographic evaluation demonstrated soft-tissue swellings and para-articular erosions involving hands (Figure 1E-F). The serum creatinine and uric acid levels were elevated as follows, creatinine, 562 μmol per liter (normal range, 31.8 to 116); and uric acid, 621 μmol per liter (normal range, 90 to 420). Figure 1. Tophi detected by different imaging methods. A.A picture of the mass anterior to the thyroid cartilage; B. A mass anterior to the thyroid cartilage detected by ultrasound; C. The mass anterior to the thyroid cartilage detected by dual energy CT; D. The mass anterior to the thyroid cartilage detected by CT scan; E. a picture of tophi in the hands; F. a plain radiograph of tophi in the hands. Conclusion DECT has more advantages over ultrasound and CT for detection of atypical tophi in gout patients. Disclosure of Interests Yutong Jiang Grant/research support from: Scientific and Technological Planning Project of Guangzhou City [grant number 202102020150], Xinyu Wu: None declared, Zetao Liao: None declared, Jun Qi: None declared, Jieruo Gu: None declared
Dynamic rewiring of biological activity across genotype and lineage revealed by context-dependent functional interactions
Authors: Eiru Kim, Lance C. Novak, Chenchu Lin, Medina Colic, Lori L. Bertolet, Veronica Gheorghe, Christopher A. Bristow, Traver Hart
Journal: Genome biology (2022)

Abstract Background Coessentiality networks derived from CRISPR screens in cell lines provide a powerful framework for identifying functional modules in the cell and for inferring the roles of uncharacterized genes. However, these networks integrate signal across all underlying data and can mask strong interactions that occur in only a subset of the cell lines analyzed. Results Here, we decipher dynamic functional interactions by identifying significant cellular contexts, primarily by oncogenic mutation, lineage, and tumor type, and discovering coessentiality relationships that depend on these contexts. We recapitulate well-known gene-context interactions such as oncogene-mutation, paralog buffering, and tissue-specific essential genes, show how mutation rewires known signal transduction pathways, including RAS/RAF and IGF1R - PIK3CA , and illustrate the implications for drug targeting. We further demonstrate how context-dependent functional interactions can elucidate lineage-specific gene function, as illustrated by the maturation of proreceptors IGF1R and MET by proteases FURIN and CPD . Conclusions This approach advances our understanding of context-dependent interactions and how they can be gleaned from these data. We provide an online resource to explore these context-dependent interactions at diffnet.hart-lab.org.
AB1262 PERFORMANCE OF JADAS-ESR AND JADAS-CRP IN THE ASSESSMENT OF DISEASE ACTIVITY IN TUNISIAN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS
Authors: R. Ben Aissa, D. Ben Nessib, H. Ferjani, A. Dghaies, W. Triki, K. Maatallah, D. Kaffel, W. Hamdi
Journal: Annals of the Rheumatic Diseases (2022)

Background The Juvenile Arthritis Disease Activity Score (JADAS) is a feasible tool which consists of four items: tender (TJC) or swollen joint count (SJC), the physician and the patient’s/parent’s global assessment and the erythrocyte sedimentation rate (ESR). C-reactive protein (CRP) has also been suggested as an alternative inflammatory marker. Objectives To compare the performance of JADAS-ESR and JADAS-CRP in the evaluation of JIA activity. Methods Twenty nine patients who met the International League of Associations for Rheumatology (ILAR) criteria for JIA were enrolled in the study. Disease activity was assessed by the JADAS-ESR and JADAS-CRP scores at 54 consultations, 29 at baseline and 25 during the last follow-up consultation. Data of JIA subtypes, disease duration and treatment were retrospectively collected from medical records. All data were checked for normality by the Kolmogorov-Smirnov test. The Spearman correlation was used for data analysis and p values less than 0.05 were considered statistically significant. Results The mean age of our population was 13.1±4.2 years [4-21] and the sex ratio of males to females was 1.07. The mean disease duration was 4.69±3.26 years [0.3-13]. JIA subtypes were: enthesis-related arthritis (n=12), polyarthritis (n=7), oligoarthritis (n=6), undifferentiated (n=3) and psoriatic arthritis (n=1). At baseline most of our patients (51,73%) were not under treatment, 34.49% were under non-steroidal anti-inflammatory drugs (NSAIDs) and 13.8% under methotrexate (MTX). At the last follow-up consultation 41.38% of the patients were under MTX, 34.49% under NSAIDS and 10.35% under TNF inhibitor (Etanercept). At baseline JADAS-ESR1 was correlated to JADAS-CRP1 (p&lt;0.001, r=0.808) in all AIJ subtypes. JADAS-ESR1 and JADAS-CRP1 were not correlated to ESR1 (p=0.416, p=0.661) nor to CRP1 (p=0.376, p=0.058). Both JADAS-ESR1 and JADAS-CRP1 were correlated to TJC1 (p&lt;0.0001, r=0.643; p=0.015, r=0.502) and only JADAS-ESR1 was correlated to SJC1 (p=0.012, r=0.461). At the last follow-up consultation, correlations were observed between JADAS-ESR2 and JADAS-CRP2 (p&lt;0.001, r=0.992) in all AIJ subtypes. JADAS-ESR2 and JADAS-CRP2 were both correlated to CRP2 (p=0.015, p=0.003) but not to SJC (p=0.175, p=.119), nor to ESR2 (p=0.535, p=0.426). Conclusion Our study suggests that both JADAS-ESR and JADAS-CRP correlate closely during the follow-up of JIA. JADAS-CRP could be recommended for assessing disease activity in JIA. Disclosure of Interests None declared
POS0973 INFLUENCE OF ANATOMICAL VARIATION OF THE SACROILIAC JOINTS ON INFLAMMATORY LESIONS ON MAGNETIC RESONANCE IMAGING
Authors: K. Ziegeler, S. T. Ulas, D. Poddubnyy, F. Proft, V. Rios Rodriguez, J. Rademacher, K. G. Hermann, T. Diekhoff
Journal: Annals of the Rheumatic Diseases (2022)

Background Anatomical variation of the sacroiliac (SI) joints is more common among patients with LBP than healthy controls; increased biomechanical strain to the joint may play a role in axial spondyloarthritis (axSpA). Objectives To assess the association of lesions joint shape variation on inflammatory lesions on SI joint magnetic resonance imaging (MRI) in patients with axSpA. Methods In this post-hoc analysis a total of 684 patients from four different prospective cohorts were evaluated (379 axSpA). Two readers independently scored all patients for joint form, erosion, sclerosis, fat metaplasia and bone marrow edema (BME). Logistic regression analyses were used to assess the association of lesions on imaging joint form; this analysis was performed separately for axSpA patients and controls. Results Typical joints were observed in 56.5% of axSpA patients (200/354) and 55.7% of control patients (169/303); in axSpA patients exhibited a significantly higher proportion of intra-articular variants (18.4% vs. 11.6%; p&lt;0.001) and crescent joint shapes (11.0% vs. 5.3.%; p&lt;0.001) than controls. AxSpA patients with intraarticular joint form variants had increased odds for erosions (OR 2.09; 95%CI 1.18-3.69) and BME (OR 1.79; 95%CI 1.13-2.82); this association was not seen in controls. Accessory joints increased the odds for sclerosis in axSpA patients (OR 2.54;95%CI 1.10-5.84) and for BME (2.05; 95%CI 1.03-4.07) and sclerosis (OR 17.91; 95%CI 6.92-46.37) in controls. Conclusion Joint form variations are associated with inflammatory lesions on SI joint MRI of axSpA patients but not controls; this indicates a role for atypical joint forms in sacroiliitis. References [1]Ziegeler, K., Kreutzinger, V., Proft, F., Poddubnyy, D., Hermann, K. G. A., &amp; Diekhoff, T. (2021). Joint anatomy in axial spondyloarthritis: strong associations between sacroiliac joint form variation and symptomatic disease. Rheumatology (Oxford). doi:10.1093/rheumatology/keab318 Disclosure of Interests Katharina Ziegeler Grant/research support from: Received research grant from the Assessment of Spondyloarthritis international Society (ASAS)., Sevtap Tugce Ulas: None declared, Denis Poddubnyy Speakers bureau: AbbVie, Eli Lilly, MSD, Novartis, Pfizer, Bristol-Myers Squibb, Roche, UCB, Biocad, GlaxoSmithKline and Gilead, Grant/research support from: AbbVie, Eli Lilly, MSD, Novartis, Pfizer, Fabian Proft Speakers bureau: Novartis, Eli Lilly, UCB, AbbVie, AMGEN, BMS, Hexal, Janssen, MSD, Pfizer and Roche, Grant/research support from: Novartis, Eli Lilly and UCB, Valeria Rios Rodriguez Speakers bureau: AbbVie and Falk e.V, Judith Rademacher: None declared, Kay-Geert Hermann Speakers bureau: AbbVie, MSD, and Novartis, Employee of: Co-owner of the BerlinFlame GmbH, Torsten Diekhoff Speakers bureau: MSD, Novartis and Eli Lilly
POS0631 EVEN LOW-DOSE GLUCOCORTICOID USE IS A RISK FACTOR FOR CLINICAL FRACTURES IN PATIENTS WITH RHEUMATOID ARTHRITIS: TEN-YEAR FINDINGS OF THE TOMORROW STUDY
Authors: C. Yoshimura, T. Koike, K. Mamoto, T. Okano, Y. Sugioka, M. Tada, K. Inui, H. Nakamura
Journal: Annals of the Rheumatic Diseases (2022)

Background Patients with rheumatoid arthritis (RA) who have sarcopenia and stiff or painful joints might be at increased risk of falls and fractures. Objectives The present study aimed to prospectively identify the incidence of clinical fractures and associated risk factors in patients with RA in a cohort study named the TOMORROW (UMIN000003876) that started in 2010. Methods We evaluated anthropometric parameters, bone mineral density (BMD), disease activity, RA medication at entry and observed the incidence of clinical fractures during ten years in 202 patients with RA (mean age, 58.6 y; medication with biological agents, 54.9%) and 202 age- and sex-matched non-RA volunteers (Vo) (mean age, 57.4 y). We compared the incidence of clinical fractures between patients with RA and Vo for ten years, and analyzed the risk factors for clinical fractures using Cox proportional hazard model. Results The incidences of clinical fractures were 0.036 and 0.024/person-year in patients with RA and Vo, respectively. Cox proportional hazard model revealed that low BMD at the thoracic vertebrae (&lt; 0.7 g/cm 2 ) and history of fractures at entry were significantly associated with the incidence of clinical fractures (Hazard ratio [HR]1.737, p=0.020 and HR1.514, p=0.047, respectively) in all participants. RA morbidity, however, was not (HR1.398, p=0.112). In patients with RA, medication with GC at entry was a significant risk factor for clinical fractures (HR1.898, p=0.017). Additionally, a mean GC dose (≥ 2 mg/day) at entry and during the ten-year period increased risk for fractures (HR 2.189, p=0.004, 1.866, p=0.022, respectively). Conclusion RA per se was not a risk factor for clinical fractures in this cohort. Low BMD at the thoracic vertebrae at entry and the use of GC with even low dose at entry and during ten years were significantly associated with an increased frequency of clinical fractures among patients with RA. Disclosure of Interests None declared
AB1577-PARE DO MOROCCAN PATIENTS DISCUSS WITH THEIR RHEUMATOLOGISTS ABOUT DIET AS PART OF THE MANAGEMENT OF THEIR OSTEOARTHRITIS?
Authors: N. El Mansouri, T. Fatima Zahrae, R. Bensaid, N. Takhrifa, H. Fouzia, B. Khadija, F. Abourazzak
Journal: Annals of the Rheumatic Diseases (2022)

Background The question of diet is frequently asked by patients with osteoarthritis. Beyond the effect of weight on the worsening of their symptoms, patients often ask whether certain foods, labelled as inflammatory or anti-inflammatory, can improve or worsen their disease. Objectives The aim of our study is to find out whether patients with osteoarthritis discuss diet during their medical visits and to investigate the association between patients’s reported dietary beliefs and practices and their willingness to discuss them. Methods This is a survey based on a questionnaire that included all patients followed for osteoarthritis who presented to the rheumatology department. The questionnaire consists of 3 parts: 1) Socio-demographic data, co-morbidities, and information on osteoarthritis (location, duration of evolution, functional impact and treatments), 2) Patients’s beliefs and attitudes about diet in relation to osteoarthritis 3) Discussions about diet during medical visits and whether there is any patient interest in such discussions. Results At that time we included 120 patients. The average age was 57.1 ± 11.8, 88.3% of the patients were women, 41.2% had comorbidities, 62.5% were illiterate. The median duration of evolution of osteoarthritis was 4 years [2; 7]. 64.2% of the patients were followed for Gonarthrosis, 25% for Discarthrosis and 10.8% for Digital osteoarthritis. The average BMI was 27.8 ± 5.2. 8.3% of the patients thought that diet influenced their osteoarthritis. 9.5% of the subjects stated that food had an effect on their symptoms, with 9.2% reporting an improvement and 8.3% an aggravation. 6.7% of patients reported food avoidance behaviours, while 10.8% adopted certain diets in order to relieve joint symptoms. Only 2.5% of the patients reported having ever had discussions about diet with their rheumatologists while 99.2% showed interest in such discussions. For those who had never done so, the main reason was that the rheumatologist had never broached the subject. In uni and multi-variate analysis, the experience of a food that improves symptoms (OR: 13; 95% CI [1,258-134,333]; p=0.019) and the adoption of dietary practices (OR: 13; 95% CI [1,258-134,333]; p=0.019) were associated with discussing diet. Conclusion Discussions about diet are reported by a minority of osteoarthritis patients and seem to be mainly related to patients’s experiences with certain foods that improve their symptomatology and also to patients’ adoption of certain diets. This situation needs to be improved as nutritional advice should be an integral part of the management of our patients. Disclosure of Interests None declared
AB0102 GPX4 - ASSOCIATED FERROPTOSIS OF MACROPHAGE EXACERBATES IMMUNE IMBALANCE IN RHEUMATOID ARTHRITIS
Authors: Y. Liu, Y. Jiang, Y. Pan
Journal: Annals of the Rheumatic Diseases (2022)

Background Reactive oxygen species accumulation and iron overload are involved in the pathogenesis of rheumatoid arthritis (RA). Ferroptosis, as a non-apoptotic form of programmed cell death, characteristically depends on iron and lipid peroxidation. However, the role of ferroptosis in RA has not been explored. Objectives To explore the role of ferroptosis in immune imbalance of rheumatoid arthritis. Methods Iron content in synovial fluid was determined by colorimetry. Lipid peroxidation was assessed by flow cytometry and immunofluorescence. MDA and GSH were used as markers to assess iferroptosis. K/BxN spontaneous arthritis mice and serum-induced arthritis mice were used as in vivo animal models of ferroptosis. Results Iron overload and hyperlipid peroxidation of mononuclear-macrophages were found in the synovial fluid of RA patients. Liproxstatin-1, the specific inhibitor of ferroptosis, alleviated the progression of arthritis mice model by increasing M2-like macrophage numbers. Mechanistically, iron overload in arthritis lesion induced anti-inflammatory macrophage ferroptosis by promoting glutathione peroxidase 4 (GPX4, a classical anti-ferroptosis molecule) to undergo P62 - dependent autophagy degradation. Conclusion Our results provide compelling evidence that macrophages ferroptosis plays a major role in RA. M2-like macrophages are more sensitive to ferroptosis than M1-like macrophages under iron overload circulation. This finding heavily contributes to the immune imbalance of rheumatoid arthritis. References [1]Xin Chen, et al. Cellular degradation systems in ferroptosis. Cell Death &amp; Differentiation, (2021) 28:1135–1148. [2]Pengchong Li,et al. Glutathione peroxidase 4-regulated neutrophil ferroptosis induces systemic autoimmunity. Nat Immunol, 2021 Sep;22(9):1107-1117. [3]Alexandr A Kapralov, et al. Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death. Nat Chem Biol, 2020 Mar;16(3):278-290. Disclosure of Interests Yan Liu Grant/research support from: the National Natural Science Foundation of China (82101899), China Postdoctoral Science Foundation Grant (2021M693658), Yutong Jiang Grant/research support from: Basic and Applied Basic Research Fund Project of Guandong Province [2021A1515111172], yunfeng pan: None declared